Moreover, Solanki et al. demonstrated that treatment of smoke-exposed and TKI-resistant NSCLC cells with a FAK inhibitor restored their sensitivity to erlotinib, correlating with PI3K signaling activity [38]. The gene discussed is PTK2; the disease is non-small cell lung carcinoma.